Partner Headlines - ARNA

  1. Pharmacological Advancements in Neuroscience Drug Discovery & ...

    Benzinga
  2. Orexigen Soars On Obesity Drug's Surprise Health Boon

    IBD
  3. Morning Market Losers

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. 10 Stocks You Should Be Watching Today

    Benzinga
  6. Arena Pharmaceuticals Misses Q4 Expectations

    Benzinga
  7. Earnings Scheduled For March 2, 2015

    Benzinga
  8. CNBC's Stock Pops & Drops From January 21

    Benzinga
  9. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  10. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  11. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  12. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  13. Morning Market Losers

    Benzinga
  14. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  15. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  18. 5 Obesity Stocks Investors Are Watching

    Benzinga
  19. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  20. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  21. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  22. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  23. Morning Market Gainers

    Benzinga
  24. Benzinga's Top #PreMarket Gainers

    Benzinga
  25. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  26. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  27. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  28. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  29. Benzinga's Top #PreMarket Gainers

    Benzinga
  30. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  31. Earnings Scheduled For November 3, 2014

    Benzinga
  32. 3 Pharma Companies Fighting Obesity

    Benzinga
  33. Benzinga's Top #PreMarket Gainers

    Benzinga
  34. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  35. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  36. Earnings Scheduled For August 1, 2014

    Benzinga
  37. Benzinga's Top #PreMarket Losers

    Benzinga
  38. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  39. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  40. Benzinga's Top #PreMarket Losers

    Benzinga
  41. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  42. FDA delays Orexigen drug

    IBD
  43. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  44. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  45. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  46. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  47. Earnings Scheduled For May 12, 2014

    Benzinga
  48. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  49. Benzinga's Top #PreMarket Losers

    Benzinga
  50. Earnings Scheduled For February 27, 2014

    Benzinga
  51. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  52. Top Trending Tickers On StockTwits For February 14

    Benzinga
  53. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  54. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  55. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  56. The Top Five Drug Launches Of 2013

    IBD
  57. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  58. Benzinga's Top #PreMarket Gainers

    Benzinga
  59. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  60. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  61. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  62. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  63. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  64. Benzinga's Top #PreMarket Losers

    Benzinga
  65. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  66. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  67. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  68. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  69. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  70. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  71. Benzinga's Top Pre-Market Losers

    Benzinga
  72. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  73. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  74. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  75. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  76. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  77. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  78. Stocks Hitting 52-Week Lows

    Benzinga
  79. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  80. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  81. Stocks Hitting 52-Week Lows

    Benzinga
  82. Stocks Hitting 52-Week Lows

    Benzinga
  83. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  84. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  85. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  86. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  87. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  88. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  89. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  90. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  91. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  92. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  93. Vivus fell 4.2% to 13.72

    IBD
  94. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  95. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  96. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  97. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  98. Benzinga's Top Pre-Market Gainers

    Benzinga
  99. The Best Small Cap Performers of 2012

    Benzinga
  100. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
Trading Center